Sophie G Kellaway and Prof Bonifer @unibirmingham #AML #Cancer #Research Different mutant RUNX1 oncoproteins program

Sophie G Kellaway and Prof Bonifer @unibirmingham #AML #Cancer #Research Different mutant RUNX1 oncoproteins program

User Photo

1 month
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0

Sophie G Kellaway and Prof Constanze Bonifer from the Institute of Cancer and Genomic Sciences, University of Birmingham speaks about the Different mutant RUNX1 oncoproteins program alternate haematopoietic differentiation trajectories.


Importance:  In patients with early-onset AC, the unique spectrum of somatic cancer gene variations is largely undetermined.


Plan, environment, and participants: This cohort study included individuals diagnosed with pathologically confirmed AC aged 18 years and older. The International Clinicogenomic Data Sharing Consortium American Association for Cancer Research Project Genomics Proof Neoplasia Knowledge Exchange reported cases with clinical-grade targeted sequencing data from January 1, 2011, to December 31, 2019. (GENIE). From May to September 2020, data analysis was performed.

Age at onset of illness. Key results and measures: The prevalence and range of somatic variance are determined in patients with AC. Using multivariable logistic regression with adjustment for sex, race/ethnicity, histological subtype, sequencing core, and sample type, variance comparisons were examined between early-onset and late-onset AC.

A total of 385 individuals with AC were included in this study (mean [SD] age at diagnosis, 56.0 [12.4] years; 187 [48.6 percent] males; 306 [79.5 percent] non-Hispanic White individuals), and 109 patients (28.3 percent) were diagnosed with early-onset AC. Race/ethnicity ranged by age at disease onset; a greater proportion of early-onset versus late-onset cases is accounted for by non-Hispanic Black individuals (9 of 109 [8.3 percent] vs 11 of 276 [4.0 percent]; P = 0.04). Patients with early-onset AC have slightly higher chances of presenting with nonsilent differences in PIK3CA, SMAD3, and TSC2 compared to patients 50 years of age or older at diagnosis (PIK3CA: odds ratio [OR], 4.58; 95 percent CI, 1.72-12.21; P = .002; SMAD3: OR, 7.37; 95 percent CI, 1.24-43.87; P = .03; TSC2: OR, 12.43; 95 percent CI, 1.03-149.59; P = .047). Patients with early-onset AC, on the other hand, had a 60% decreased risk of presenting with non-silent GNAS differences compared to patients with late-onset AC (OR, 0.40; 95% CI, 0.21-0.76, P = .006). By histologic subtype, young patients with appendix mucinous adenocarcinoma had a 65% decrease in the chances of GNAS variance relative to late-onset patients in the modified models (OR, 0.35; 95% CI, 0.15-0.79; P = .01). Similarly, patients with early-onset nonmucinous appendiceal adenocarcinomas had a 72% decrease in GNAS variance odds relative to late-onset cases, although these results did not achieve significance (OR, 0.28; 95% CI, 0.07-1.14; P = .08). GNAS and TP53 differences in early-onset and late-onset cases (P < .05) were mutually exclusive in its.

Conclusions and Pertinence:
In the study, relative to AC diagnosed among older individuals, AC diagnosed among younger individuals had a distinct genomic landscape. Specifically for younger patients, the creation of therapeutic modalities that target these unique molecular features can produce clinical implications.

Link To Abstract -

Up Next Autoplay